Food intake increases the activity of hepatic de novo lipogenesis, which mediates the conversion of glucose to fats for storage or use. In mice, this program follows a circadian rhythm that peaks with nocturnal feeding 1,2 and is repressed by Rev-erba/b and an HDAC3-containing complex 3-5 during the day. The transcriptional activators controlling rhythmic lipid synthesis in the dark cycle remain poorly defined. Disturbances in hepatic lipogenesis are also associated with systemic metabolic phenotypes [6] [7] [8] , suggesting that lipogenesis in the liver communicates with peripheral tissues to control energy substrate homeostasis. Here we identify a PPARd-dependent de novo lipogenic pathway in the liver that modulates fat use by muscle via a circulating lipid. The nuclear receptor PPARd controls diurnal expression of lipogenic genes in the dark/feeding cycle. Liver-specific PPARd activation increases, whereas hepatocytePpard deletion reduces, muscle fatty acid uptake. Unbiased metabolite profiling identifies phosphatidylcholine 18:0/18:1 (PC(18:0/ 18:1) as a serum lipid regulated by diurnal hepatic PPARd activity. PC(18:0/18:1) reduces postprandial lipid levels and increases fatty acid use through muscle PPARa. High-fat feeding diminishes rhythmic production of PC(18:0/18:1), whereas PC(18:0/18:1) administration in db/db mice (also known as Lepr 2/2 ) improves metabolic homeostasis. These findings reveal an integrated regulatory circuit coupling lipid synthesis in the liver to energy use in muscle by coordinating the activity of two closely related nuclear receptors. These data implicate alterations in diurnal hepatic PPARd-PC(18:0/18:1) signalling in metabolic disorders, including obesity.
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Food intake increases the activity of hepatic de novo lipogenesis, which mediates the conversion of glucose to fats for storage or use. In mice, this program follows a circadian rhythm that peaks with nocturnal feeding 1, 2 and is repressed by Rev-erba/b and an HDAC3-containing complex [3] [4] [5] during the day. The transcriptional activators controlling rhythmic lipid synthesis in the dark cycle remain poorly defined. Disturbances in hepatic lipogenesis are also associated with systemic metabolic phenotypes [6] [7] [8] , suggesting that lipogenesis in the liver communicates with peripheral tissues to control energy substrate homeostasis. Here we identify a PPARd-dependent de novo lipogenic pathway in the liver that modulates fat use by muscle via a circulating lipid. The nuclear receptor PPARd controls diurnal expression of lipogenic genes in the dark/feeding cycle. Liver-specific PPARd activation increases, whereas hepatocytePpard deletion reduces, muscle fatty acid uptake. Unbiased metabolite profiling identifies phosphatidylcholine 18:0/18:1 (PC(18:0/ 18:1) as a serum lipid regulated by diurnal hepatic PPARd activity. PC(18:0/18:1) reduces postprandial lipid levels and increases fatty acid use through muscle PPARa. High-fat feeding diminishes rhythmic production of PC(18:0/18:1), whereas PC(18:0/18:1) administration in db/db mice (also known as Lepr
2/2
) improves metabolic homeostasis. These findings reveal an integrated regulatory circuit coupling lipid synthesis in the liver to energy use in muscle by coordinating the activity of two closely related nuclear receptors. These data implicate alterations in diurnal hepatic PPARd-PC(18:0/18:1) signalling in metabolic disorders, including obesity.
PPARd promotes fatty acid (FA) synthesis in the liver 9 . Surprisingly, hepatic PPARd overexpression (adenoviral-mediated, adPPARd) reduced circulating triglyceride (TG) and free fatty acid (FFA) levels (Fig. 1a) . FA uptake and b-oxidation were increased in isolated soleus muscle, compared to control mice (adenoviral-mediated green fluorescent protein expression, adGFP) (Fig. 1b) , indicating that a PPARd-dependent signal couples liver lipid metabolism to muscle FA oxidation. To identify candidate molecules, we performed untargeted liquid chromatography-mass spectrometry (LC-MS)-based metabolite profiling of hepatic lipids 10, 11 . Metabolite set enrichment analyses ranked acetyl-CoA carboxylase (Acaca, also known as Acc1, a rate-limiting enzyme in de novo lipogenesis) as a top altered pathway in the adPPARd/adGFP comparison (Extended Data Fig. 1a and Extended Data Table 1 ), consistent with a positive correlation of ACC1 (also known as ACACA) and PPARD expression in human livers (Extended Data Fig. 1b) . Transient liverspecific Acc1 knockdown (LACC1KD) reduced hepatic TG content and increased serum TG and FFA levels (Fig. 1c) . FA uptake was decreased in isolated soleus muscle from LACC1KD mice (Fig. 1d) . In vivo FA uptake assays revealed that muscle FA uptake was decreased in LACC1KD mice in the dark/feeding cycle, when the lipogenic program is active (zeitgeber time (ZT) ZT 18 or 12 a.m.; ZT 0: lights on at 6 a.m.; ZT 12 : lights off at 6 p.m.) (Fig. 1e ). This defect was accompanied by slower clearance of circulating [ 3 H]oleic acid (Fig. 1f) . These results demonstrate that hepatic de novo lipogenesis is linked to muscle FA use.
Ppard expression oscillated diurnally, peaking at night, coincident with messenger RNA (mRNA) levels of the molecular clock Bmal1 (also known as Arntl) in the liver and in dexamethasone-synchronized primary hepatocytes (Extended Data Fig. 2a, b) . In liver-conditional Ppard knockout (LPPARDKO) mice, induction of hepatic Acc1 during the dark cycle was abolished; diurnal expression of Acc2, fatty acid synthase (Fasn) and stearoyl-CoA desaturase 1 (Scd1) was also altered (Fig. 2a) , indicating that PPARd regulates rhythmic lipogenic gene expression in the liver. Daytime-restricted feeding reversed expression patterns of all major molecular clocks (Extended Data Fig. 2c ) 12 . Peak mRNA levels of Ppard and lipogenic genes also shifted to the light cycle in control but not in LPPARDKO mice (Fig. 2b) . The expression of diglycerol acyltransferase (Dgat1, triglyceride synthesis), choline kinase a (Chka, phosphocholine synthesis) and core circadian clock genes were unchanged in LPPARDKO mice (Extended Data Fig. 2a, c) . Body weight, feeding activity and insulin sensitivity were similar between genotypes (Extended Data Fig. 2d , e and Extended Data Table 2 ). LPPARDKO reduced muscle FA uptake in the dark cycle in vivo (Fig. 2c) , mirroring results from LACC1KD mice and demonstrating a functional consequence of this hepatic transcriptional circuitry in muscle physiology.
Products of de novo lipogenesis can exert signalling effects, for example, palmitoleate as a lipokine and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine as an endogenous ligand of the nuclear receptor PPARa in hepatocytes 13, 14 . In humans and mice, serum lipid composition closely resembles that of the liver 15 (Extended Data Fig. 2f ), suggesting that changes in hepatic de novo lipogenesis may have systemic metabolic effects. Indeed, serum or serum-derived lipid extracts -but not delipidated serum -collected in the dark cycle from wild-type mice increased FA uptake in C2C12 myotubes (versus LPPARDKO, Fig. 2d, e) . Solid phase extraction of plasma lipids (Extended Data Fig. 2g ) identified that the phospholipid fraction stimulated FA uptake in myotubes (Fig. 2f) .
To identify phospholipids mediating functional interactions between PPARd, hepatic lipid synthesis and muscle FA use, we profiled serum lipid metabolites of samples from wild-type and LPPARDKO mice collected at six ZT points. 735 unique ion features were detected in positive and negative ionization modes (Extended Data Fig. 2f ). Metabolite hierarchical clustering revealed the main differences between wild-type and LPPARDKO serum occurred during the dark cycle (Fig. 3a, b) , when PPARd-controlled lipogenesis is most active. Daytime feeding led to a more pronounced discordance in serum lipidomes between these two genotypes, indicating that LPPARDKO mice were unable to adjust their lipogenic gene expression program (Extended Data Fig. 3a, b) . Principal component analysis (PCA) of features in positive ionization mode, which detects phospholipids as well as mono-, di-and triacylglycerols, demonstrated co-clustering of LPPARDKO and LACC1KD serum samples from the dark cycle (Extended Data Fig. 3c ). Comparison of serum and liver metabolomes from three relevant models, LPPARDKO, LACC1KD and adPPARd, in positive ionization mode (Supplementary Data) yielded 14 features altered in all three models (Fig. 3c, d ).
These 14 lipid species were also the main drivers of the sample clustering in PCA analyses (Extended Data Fig. 3d ). We focused on m/z 5 788.6, putatively identified as PC(36:1), as its levels were decreased in both LPPARDKO and LACC1KD (versus control) serum but increased in liver tissue from PPARd-overexpressing mice (Fig. 3d) , correlating with the FA uptake data observed in each model. The extracted ion chromatogram (EIC) showed this phospholipid displayed diurnal rhythmicity peaking at night (or during the day in daytime restricted feeding) in wild-type serum, but not in LPPARDKO serum (Extended Data Fig. 3e, f) . This phospholipid was also reduced in LACC1KD serum and increased in adPPARd liver lysates (Extended Data Fig. 3e ). Co-elution experiments with authentic PC(18:0/18:1) (also known as 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine, SOPC) and tandem mass spectrometry scanning 16 (Fig. 3e) . PPARd synthetic ligand treatment (GW501516, 4 days) increased serum PC(18:0/18:1) levels in wild-type mice but not in LPPARDKO mice (Fig. 3f) . These data identified PC(18:0/18:1) as a serum lipid regulated by hepatic PPARd diurnally in three mouse models.
Intraperitoneal injection of escalating concentrations of PC(18:0/18:1) reduced serum TG and FFA levels (Extended Data Fig. 3h) , with a trend of increased muscle FA uptake. Tail-vein injection of PC(18:0/18:1) (5 mg kg 21 body weight) also reduced serum TG (Fig. 3g) . Notably, PC(16:0/18:1) and PC(18:1/18:1) had no effect. In myotubes, only PC(18:0/18:1) increased FA uptake (Fig. 3h) . Catheter-based, continuous infusion of PC(18:0/18:1) (25 mg min 21 kg 21 for 200 min) through the jugular vein also lowered circulating TG and FFA levels (Fig. 3i ). As such, PC(18:0/18:1) links the hepatic PPARd-controlled lipogenic program to serum lipid concentrations and muscle fat use.
Mechanistically, several FA use genes in the muscle, namely Cd36, Fabp3, Fabp4, Fatp1 (also known as Slc27a1), Fatp4 (also known as Slc27a4), Ppara, Cidea and Acadm, were induced in adPPARd and/ or PC(18:0/18:1)-treated mice, but repressed in LPPARDKO and LACC1KD animals (Fig. 4a ). Cd36 and Fabp3 are known mediators 
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of muscle FA uptake 17, 18 . Cd36 expression at mRNA and protein levels also oscillated in wild-type muscle peaking in the dark cycle, and shifted to the light cycle by daytime restricted feeding ( Fig. 4c, d ). PPARa controls FA metabolism in muscle 19 and can be activated by certain PCs 14 . In reporter assays, PC(18:0/18:1) moderately activated PPARa (Extended Data Fig. 4e) . However, the effects of PC(18:0/18:1) infusion on reducing serum TG levels and increasing muscle FA uptake and Cd36/ Fabp3 expression were abolished in Ppara knockout (PPARaKO) mice (Fig. 4d, e) . In myotubes, increased FA uptake by PC(18:0/18:1) was diminished by Ppara knockdown or by a Ppara mutant lacking the carboxy-terminus activation function domain (AF2), indicating that PC(18:0/18:1) or its metabolites may modulate PPARa transcriptional activity in vivo (Fig. 4f ). These findings demonstrate that a hepatic PPARd-PC(18:0/18:1)-muscle PPARa signalling cascade coordinates fat synthesis and use.
Obesity alters circadian rhythms in multiple tissues, resulting in abnormal metabolism 20 . Diet-induced obesity altered the rhythmic pattern of serum PC(18:0/18:1) (Extended Data Fig. 4f, g ). In db/db mice (a genetic model of obesity), tail-vein injection of PC(18:0/18:1) (5 mg kg 21 day 21 for 6 days) reduced fasting TG and FFA levels (Fig. 4g) . Non-fasting blood glucose levels trended lower in PC(18:0/ 18:1)-treated animals (Extended Data Fig. 4h ). PC(18:0/18:1) reduced fasting glucose and improved glucose tolerance test results (Fig. 4h and Extended Data Table 2 ). Glucose concentrations throughout insulin tolerance test were lower with PC(18:0/18:1) treatment (Fig. 4h) , although the per cent change did not differ. Fasting insulin levels were similar (Extended Data Table 2 ). Muscle lipid contents in the PC(18:0/18:1)-treated group trended lower (Fig. 4i) , consistent with the notion that PC(18:0/18:1) promotes fat use in the muscle.
The data presented here reveal that diurnal oscillations of hepatic de novo lipogenesis-derived lipid metabolites coordinate metabolic functions between liver and muscle (Extended Data Fig. 4i ). The finding also adds PC(18:0/18:1) to an emerging network of signalling molecules mediating inter-organ communications 13, [21] [22] [23] [24] . The approximately twofold change in PC(18:0/18:1) concentrations is similar to other lipid mediators, including two gut-derived lipids that regulate satiety: N-acylphosphatidylethanolamine and oleylethanolamide 21, 22 , suggesting that physiological fluctuations in levels of lipid mediators are sufficient to stimulate specific biological functions. Specificity is further supported by data showing that systemic treatment with PC(16:0/18:1), a hepatic PPARa ligand 14 , did not lower serum TG or stimulate FA uptake (Fig. 3g, h ), nor did it activate PPARa in muscle cells (Extended Data Fig. 4j, k ). An association between serum PC(36:1) levels and diabetes mellitus in humans has recently been reported 
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Functional assays. In vitro FA uptake: C2C12 myotubes were pre-treated with lipids complexed in 0.2 % FA-free BSA overnight. Cells were washed before subjecting to a 5 min FA loading with 1 mCi ml 21 Data Fig. 5, 6 ) and statistical tests are described in Methods. Data are presented as mean 6 s.e.m. Information for mouse cohorts and primer sequences are described in Extended Data Tables 3,  4 . For in vitro assays, the mean and s.e.m. were determined from 3-4 biological replicates for one representative experiment. Experiments were repeated at least three times. Significance was set at P , 0.05.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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Materials
. Ppard or GFP adenovirus was generated as described 9 . The shScramble and shAcc1 adenovirus were provided by C. Newgard 30 . Small hairpin RNA sequences against Cd36
31
, Ppara (59-CCCTTATCTGAAGAATTCTTA-39) or luciferase (control) were cloned in the pSIREN-RetroQ vector. PparaAF2 mutant construct was generated through site-directed mutagenesis to introduce a stop codon in front of the AF2 domain using wild-type Ppara construct as the template. The oligonucleotide used for mutagenesis was: 59-GAGCATGCGCAGCTCGA GTAGGTCATCAAGAAGACC-39. Full-length Ppara or PparaAF2 mutant complementary DNA was cloned in the pBabe retroviral vector. Cell lines. All cell lines were obtained from ATCC: C2C12 (CRL-1772); HEK293 (CRL-1573). C2C12 myoblasts were infected with retroviral particles and selected against puromycin to generate stable lines. All stable C2C12 myoblasts were able to differentiate into myotubes with no apparent defects. Differentiation of C2C12 myoblasts was performed in 2% horse serum, high-glucose DMEM for 8 days. FA uptake/oxidation assays. In vitro FA uptake. C2C12 myotubes were pretreated with lipids complexed in 0.2% BSA (FA-free) overnight. Cells were thoroughly washed before subjecting to a 5-min FA loading with 1 mCi ml 21 H]oleic acid in 3.5% FA-free BSA was infused through portal vein (or in 5% intralipid through jugular vein in PC(18:0/18:1) infusion experiments). Blood samples were collected at 1, 2, 5, 7 and 10 min after infusion to determine radioactivity. At 10 min, soleus and gastrocnemius muscles were isolated. FA uptake was calculated as described 29 . Animals. Mice used in the current study were on the C57BL/6J background, except for wild-type FVB/NJ and FVB/NJ-db/db mice used for PC(18:0/18:1) tail-vein injection (see Extended Data Table 3 for detail). Liver-specific Ppard knockout mice were generated by crossing albumin-cre transgenic mice to Ppard f/f mice. Ppara knockout mice (PPARaKO), FVN/NJ and FVB/NJ-db/db mice were purchased from Jackson Laboratory. Animals were on chow diet (with the exception of Extended Data Fig. 4f, g ) and housed in a barrier facility with 12-h light and dark cycles. ZT 0: lights on at 6 a.m.; ZT 12: lights off at 6 p.m. All animal studies were approved by the Harvard Medical Area Standing Committee on Animals.
Adenovirus-mediated liver-specific overexpression or knockdown. Adenovirus was injected through the tail vein (10 9 plaque-forming units per mouse). Subsequent metabolic characterizations were carried out 4 days post injection. AdPPARd/adGFP was repeated in 3 cohorts (8-10 weeks old male, n 5 4-6) and LACC1KD was conducted in 2 cohorts (8-10 weeks old male, n 5 5).
Circadian gene expression. 5 cohorts were used for circadian studies (8 weeks db/db mice. Eight-week-old male FVB/NJ-db/db mice were injected with a bolus of 5mg kg 21 body weight PC(18:0/18:1) or vehicle carried by 5% intralipid through tail vein once daily for 6 days (n 5 4-5 per treatment), followed by metabolic studies. Metabolic studies. Metabolic cage studies were performed in a Comprehensive Lab Animal Monitoring System (Columbus Instruments). Data were collected for 48 h starting at the beginning of the dark cycle. TG and FFA were determined by colorimetric methods (Thermo and Wako). Hepatic TG was determined from chloroform:methanol (2:1 v/v) extracts of vacuum dried liver samples. Glucose and insulin tolerance test were performed on overnight fasted animals. Blood glucose levels were determined at indicated time points after administration of 1.5 mg kg 21 body weight glucose or 1U kg 21 body weight insulin. Lipid extraction, fractionation and treatments. Serum lipids were diluted with PBS followed by a liquid/liquid extraction with chloroform and methanol (final concentrations of chloroform:methanol: PBS were 2:1:1 v/v). This extraction mixture phase separated to provide an aqueous layer (top) and an organic layer (bottom), which contains all lipids. The lipid-containing layer was concentrated to dryness using a constant stream of nitrogen and dissolved in chloroform, followed by fractionation using a simple column purification method, as described 32 . Briefly, aminopropyl columns (Sep-Pak Vac NH2 cartridge 3 ml per 500 mg 55-105 mm, Waters) were equilibrated 3 times with acetone/water (7:1). Lipids in chloroform were dried under nitrogen and re-dissolved in hexane/ methyl-butyl-tert-ether (MBTE)/acetic acid (100:3:0.3). Lipids were loaded onto the equilibrated column and were eluted sequentially with hexane, hexane/chloroform/ethyl acetate (100:5:5), chloroform/2-propanol (2:1) (diacylglycerol/ monoacylglycerol fraction), chloroform: methanol/acetic acid (100:2:2) (FFA fraction), and methanol/chloroform/water (10:5:4) (phospholipids fraction, Extended Data Fig. 2g ). Each fraction was dried under nitrogen and dissolved in chloroform. For in vitro experiments, lipids were dissolved in 0.2% FA-free BSA in DMEM with 2% double stripped FBS (charcoal stripped and lipoprotein deficient) and applied to cells overnight. Cells were washed extensively before functional assays. Primary hepatocytes and in vitro synchronization. Primary hepatocytes were isolated as described 33 . 100 nM of dexamethasone was applied for 1 h to synchronize cells. After thorough washing, fresh culture media was added and cells were collected at the indicated time after dexamethasone removal. Gene expression and western blots. Gene expression was determined by SYBR Green based quantitative PCR with reverse transcription (qRT-PCR) using 36b4 as an internal standard. A relative standard curve method was used to calculate the relative expression of genes. For high-throughput RT-qPCR array used for muscle gene expression, the DDC t method was used to measure relative expression. Hierarchical clustering and heat map were generated by Cluster and Java TreeView. The primers used in this study were obtained from Primer Bank 34 and listed in Extended Data Table 4 . Protein levels of CD36 were determined by western blotting of muscle lysates using antibody against CD36 (SC-9154, Santa Cruz). For circadian studies, a pooled sample from wild-type or LPPARDKO mice (n 5 4) at each time point was used. For in vivo Acc1 knockdown, the knockdown efficiency was determined by western blotting (n 5 5). Two representative animals from each group were shown (Fig. 1c) . Liquid-chromatography mass-spectrometry (LC-MS). A 2:1:1 chloroform: methanol:PBS solution was prepared for lipid extraction to isolate organic soluble metabolites. Following brief vortexing, samples were centrifuged at 2,500g at 4 uC for 10 min. The organic layer (bottom) was transferred to a new vial and solvents were evaporated under a stream of nitrogen. Samples were then dissolved in chloroform (120 ml) to provide a mass spectrometry ready solution and stored at 280 uC until LC-MS analysis (within 48 h of extraction). For both positive and negative ionization mode LC-MS runs, 20 ml of extract was injected. LC-MS analysis was performed using an Agilent 6210 Accurate-Mass time-of-flight LC-MS system as described 10, 11 . For LC analysis in negative mode, a Gemini (Phenomenex) C18 column (5 mm, 4.6 3 50 mm) was used together with a pre-column (C18, 3.5 mm, 2 3 20 mm). Mobile phase A consisted of 95:5 water:methanol and mobile phase B was composed of 60:35:5 isopropanol:methanol:water. Both A and B were supplemented with 0.1% ammonium hydroxide solution (28% in water). The flow rate for each run was 0.5 ml min
21
. The gradient started at 0% B for 5 min and linearly increased to 100% B over 40 min, was then maintained at 100% B for 8 min before re-equilibrating for 7 min at 0% B. For the LC analysis in positive mode, a Luna (Phenomenex) C5 column (5 mm, 4.6 3 50 mm) was used together with a pre-column (C4, 3.5 mm, 2 3 20 mm). Mobile phase A and B and the gradient were the same as for negative mode, but supplemented with 0.1% formic acid and 5 mM ammonium formate. MS analysis was performed with an electrospray source ionization (ESI) interface. The capillary voltage was set to 3.0 kV and the fragmentor voltage to 100 V. The drying gas temperature was 350 uC, the drying gas flow was 10 l min 21 , and the nebulizer pressure was 45 p.s.i. Data were collected using a mass range from 100-1,500 Da. For wild-type and LPPARDKO serum LETTER RESEARCH samples, all samples of each genotype from different time points were detected in a single consecutive run. To validate the results, samples from ZT 8, ZT 16 and ZT 24 were subject to a second run (Extended Data Fig. 5 ). For Scramble and LACC1KD serum or adGFP and adPPARd liver, the entire sample set was run in a single session. Targeted analysis of phosphocholine species. Side-chain composition of phosphocholine species. Phosphatidylcholine fatty acyl chain composition was analysed separately based on established conditions 15 1 to m/z 281.2 transition for all PCs. Capillary voltage was set to 3.0 kV, the fragmentor voltage to 200 V with a collision energy of 35 V. The drying gas temperature was 350 uC, the drying gas flow was 10 l min 21 and the nebulizer pressure was 45 p.s.i. The integrated peak area for each species was normalized to the peak area of the recovery standard. Data analysis (Extended Data Fig. 6 ). Data preprocessing. Raw data files were converted to mzXML files and subsequently aligned by XCMS 35 . The resulting aligned features derived from wild-type, LPPARDKO, Scramble and LACC1KD serum were compared to identify common features using metaXCMS 36 with a mass tolerance of 0.01 and retention time tolerance of 60 s. Identical procedures were carried out to generate common features from adPPARd and adGFP liver lysates. Subsequently, these features from serum and liver lysates samples were processed by an automated workflow 37 to identify isotopic peaks and assign putative identity with 3 p.p.m. mass tolerance. All isotopic peaks were removed and the remaining data were cutoff for features with median intensity less than 5 3 10 4 . The reproducibility of the untargeted metabolomics platform was evaluated from two independent runs of 6 samples. The Spearman's rank correlation coefficient was calculated and the duplicate pair with lowest correlation coefficient was plotted (Extended Data Fig. 5a ).
Data normalization. We adapted methods from ref. 38 . Briefly, each sample was centred by median and scaled by its inter-quartile range (IQR). The normalized distributions of samples were plotted in Extended Data Fig. 5b as box-and-whisker plot.
Hierarchical clustering. Both positive and negative ionization mode features from wild-type and LPPARDKO serum around the clock were mean-centred and scaled by standard deviation on a per-feature basis (auto-scaling). To simplify the visualization, only the mean value of each feature from every time point was used for the construction of heat map. The resulting data sets of each genotype were clustered using Euclidean distance as the similarity metric in Cluster 3.0. Heat maps were generated by Java TreeView. Heat map of LPPARDKO serum was aligned to wild type for comparison. Dendrogram of samples was plotted based on Spearman correlation with Ward linkage.
Principal component analysis. Auto-scaling was applied on a per metabolite basis to each biological group (wild type versus LPPARDKO and Scramble versus LACC1KD). Principal component analysis was performed in Metaboanalyst 39 . The three-dimensional view of the first 3 principal components was plotted. In addition, score plot of the first and third principal components, showing the separation between sample groups and the loading plot of these two principal components were generated (Extended Data Fig. 3c, d ).
Identification of significant features. The empirical P value for each pair of comparison was calculated by randomly permuting sample labels for 1,000 times to obtain the null distribution. The analysis was carried out in Multiple Experiment Viewer 40 . False discovery rate was determined by Benjamini-Hochberg method. A feature is considered significant for downstream cross-comparison with unadjusted P , 0.05. Significantly changed features in wild-type and LPPARDKO mice serum at night (n 5 6, pooled sample set from ZT 16 and ZT 20), Scramble and LACC1KD mice serum (n 5 5), and adGFP and adPPARd liver lysates (n 5 4) were compared and visualized in Venn diagram. A total of 158, 189 and 418 features were significantly altered in LPPARKO/wild-type (serum samples at ZT 16/ZT 20, P , 0.05, corresponding to 19.6% FDR, Supplementary Data), LACC1KD/scramble control (serum samples at ZT 16, P , 0.05, FDR 5 17%) and adPPARd/adGFP (liver lysates, P , 0.05, FDR 5 11.3%) comparisons, respectively.
Metabolites set enrichment analysis (MSEA). Significantly altered features in the adPPARd/adGFP liver lysate comparison were subjected to database search to assign putative identities. Among those, 26 were matched to human metabolites database (HMDB) (Extended Data Table 1 ). The mapped species were assigned a HMDB ID for subsequent MSEA analysis implemented in the Metaboanalyst 39 . Statistical test. Power. Owing to the multitude of measurements on each animal cohort, it is not feasible to pre-determine a sample size that achieves the same power of all subsequent measurements. Therefore, we determined the minimal number of animals required to detect a pre-defined difference in serum TG, a key readout throughout the study. Our pilot studies in wild-type mice have indicated that to detect an effect size of 50% reduction in serum TG with a power of 80%, 3-8 mice are required per group, depending on time of the day (as TG levels vary). We determined the actual number of animals used for each study based on the above sample size estimation in conjunction with the feasibility of experimental approaches. Replication. Animal experiments were performed on multiple cohorts (Extended Data Table 3 ). In vitro experiments were performed at least 3 times.
Randomization. The randomized block design was used for all animal experiments. We identified the age, sex, body weight, cage effect and timing of experiments as blocking factors. Therefore, all animal experiments were carried out on age-matched animals of the same sex. Body weight was measured before assigning treatment groups. Cage effect was controlled in pharmacological treatment studies by randomly assigning animals to the placebo or treatment group from the same cage. To control for the timing of experiments, alternating genotypes were drawn for each measurement. Subsequent assays (gene expression, PC(18:0/18:1) concentration measurement, etc) were performed in a blinded fashion, that is, every sample was assigned a number without genotype or treatment labelled and the assays were performed sequentially based on the sample number. Often, samples were intercalated from different groups.
Sample exclusion and statistical tests. Pre-determined sample exclusion criterion was established for technical failures. In addition, the 1.5 inter-quartile range rule was used to exclude additional outliers. Two-tailed unpaired student's t-test was used to compare two groups/treatments for experiments considered normal distribution (for example, cultured cells). For time-series data, the twoway ANOVA procedure was used. For metabolomics data analysis, the methods are detailed in metabolomics data analysis section. Equal variance among groups was assumed.
